Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must have previously documented CHC genotype 1 infection.~* Participant must have a liver biopsy with histology consistent with CHC and no other etiology.~* Participants with bridging fibrosis or cirrhosis must have an ultrasound within 6 months of the Screening Visit (or between Screening and Day 1) with no findings suspicious for hepatocellular carcinoma (HCC).~* Participant must be \>=18 years of age.~* Participant must weigh between 40 kg and 125 kg.~* Participant and participant's partner(s) must each agree to use acceptable methods of contraception for at least 2 weeks prior to Day 1 and continue until at least 6 months after last dose of study drug, or longer if dictated by local regulations.~* Participants must be willing to give written informed consent.~Exclusion Criteria:~* Coinfection with the human immunodeficiency virus (HIV) or hepatitis B virus (HBsAg positive).~* Participants who received prior treatment for hepatitis C; other than herbal remedies, except those with known hepatotoxicity.~* Treatment with any investigational drug within 30 days of the randomization visit in this study.~* Participation in any other clinical trial within 30 days of randomization or intention to participate in another clinical trial during participation in this study.~* Evidence of decompensated liver disease including, but not limited to, a history or presence of clinical ascites, bleeding varices, or hepatic encephalopathy.~* Diabetic and/or hypertensive participants with clinically significant ocular examination findings: retinopathy, cotton wool spots, optic nerve disorder, retinal hemorrhage, or any other clinically significant abnormality.~* Pre-existing psychiatric condition(s).~* Clinical diagnosis of substance abuse of the specified drugs within the specified timeframes.~* Any known pre-existing medical condition that could interfere with the participant's participation in and completion of the study.~* Evidence of active or suspected malignancy, or a history of malignancy, within the last 5 years (except adequately treated carcinoma in situ and basal cell carcinoma of the skin). Participants under evaluation for malignancy are not eligible.~* Participants who are pregnant or nursing. Participants who intend to become pregnant during the study period. Male participants with partners who are, or intend to become, pregnant during the study period.~* Any other condition which, in the opinion of a physician, would make the participant unsuitable for enrollment or could interfere with the participant participating in and completing the study.~* Participants who are part of the site personnel directly involved with this study.~* Participants who are family members of the investigational study staff.~* Participants who had life-threatening serious adverse event (SAE) during screening period.~* Protocol-specified hematologic, biochemical, and serologic criteria: Hemoglobin \<12 g/dL for females and \<13 g/dL for males; Neutrophils \<1500/mm\^3 (blacks: \<1200/mm\^3); Platelets \<100,000/mm\^3; Direct bilirubin \>1.5 x upper limit of normal (ULN)~* Serum albumin \< lower limit of normal (LLN)~* Thyroid-stimulating hormone (TSH) \>1.2 x ULN or \<0.8 x LLN of laboratory, with certain exceptions.~* Serum creatinine \>ULN of the laboratory reference.~* Protocol-specified serum glucose concentrations.~* protocol-specified alpha fetoprotein levels.~* Prothrombin time/partial thromboplastin time (PT/PTT) values \>10% above laboratory reference range.~* Anti-nuclear antibodies (ANA) \>1:320.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1. Placebo + PEG + RBV (Type: PLACEBO_COMPARATOR): PegIntron (PEG) 1.5 μg/kg + Ribavirin (RBV) (weight-based dosing \[WBD\]) for 4 weeks (lead in treatment) followed by placebo + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.
- 2. Boceprevir + PEG + RBV - 24 Weeks (RGT) (Type: EXPERIMENTAL): PEG 1.5 μg/kg + RBV (WBD) for 4 weeks (lead in treatment) followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 24 weeks. Participants were offered a response guided therapy (RGT) at treatment week 28.~* At the Treatment Week 28 visit, participants whose HCV-RNA was undetectable from Treatment Weeks 8 to Treatment Week 24, will proceed to the 44-week follow-up.~* At the Treatment Week 28 visit, participants with detectable HCV-RNA at Treatment Week 8 or at any subsequent assays will continue on therapy with placebo + PEG 1.5 μg/kg + RBV (WBD) for an additional 20 weeks, to complete a total of 48 weeks on treatment with 24 weeks post-treatment follow-up.
- 3. Boceprevir + PEG + RBV - 44 Weeks (Type: EXPERIMENTAL): PEG 1.5 μg/kg + RBV (WBD) for 4 weeks (lead in treatment) followed by boceprevir + PEG 1.5 μg/kg + RBV (WBD) for 44 weeks with 24 weeks post-treatment follow-up.

Based on this trial design, predict the completion outcome and termination type (if applicable).